Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.
Salizzoni
M
M
Chirurgia Generale C, Ospedale S. Giovanni Battista di Torino, Italy.
Cavallari
A
A
Risaliti
A
A
Filipponi
F
F
Gerunda
G E
GE
Forti
D
D
Fassati
L R
LR
Cillo
U
U
Castagneto
M
M
Valente
U
U
Tisone
G
G
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005006:Ethnicity; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D018579:Patient Selection; D012086:Reoperation; D012449:Safety; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D001379:Azathioprine; D016559:Tacrolimus